Hepatitis B and the need for a booster dose (Q28239937)

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Hepatitis B vaccine -- do we need boosters?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Determination of immune memory to hepatitis B vaccination through early booster response in college students.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Immune memory to hepatitis B virus in 4-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Are booster immunisations needed for lifelong hepatitis B immunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

The long-term efficacy of plasma-derived hepatitis B vaccine in babies born to carrier mothers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Long-term protection against carriage of hepatitis B virus after infant vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Long-term benefit of hepatitis B vaccination among children in Thailand with transient hepatitis B virus infection who were born to hepatitis B surface antigen-positive mothers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Vaccine induced protection against hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Hepatitis B vaccination: to boost or not to boost?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Long-term humoral and cellular immune response to hepatitis B vaccine in high-risk children 18-20 years after neonatal immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Stable seroepidemiology of hepatitis B after universal immunization in Taiwan: A 3-year study of national surveillance of primary school students.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Near elimination of hepatitis B virus infections among Hawaii elementary school children after universal infant hepatitis B vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

Boosters for hepatitis B vaccination? Need for an evidence-based policy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270

The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR270